Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
10/2005
10/06/2005WO2005092898A1 The conjugates of a hydrophilic polymer-tripterygium's extracts and the pharmaceutical compositions thereof
10/06/2005WO2005092889A1 Composition for solid pharmaceutical preparation of solifenacin or salt thereof
10/06/2005WO2005092392A2 Conjugated psychotropic drugs and uses thereof
10/06/2005WO2005092391A2 Conjugates of hydroxyalkyl starch and a protein
10/06/2005WO2005092390A2 Conjugates of hydroxyalkyl starch and a protein
10/06/2005WO2005092389A1 Composite particle and coated composite particle
10/06/2005WO2005092388A1 Liposome preparation
10/06/2005WO2005092387A1 Stable injectable diclofenac compositions
10/06/2005WO2005092380A2 Uses of anti-ctla-4 antibodies
10/06/2005WO2005092377A1 Cytotoxicity mediation of cells evidencing surface expression of cd63
10/06/2005WO2005092376A1 Cytotoxicity mediation of cells evidencing surface expression of mcsp
10/06/2005WO2005092375A1 Cytotoxicity mediation of cells evidencing surface expression of cd44
10/06/2005WO2005092369A2 Conjugates of hydroxyethyl starch and erythropoietin
10/06/2005WO2005092351A1 The medical use of graft nano-carbon
10/06/2005WO2005092347A2 Anhydrous pharmaceutical composition associating a siliconated agent and solubilised active principle
10/06/2005WO2005092336A1 Controlled-leaching preparation and process for producing the same
10/06/2005WO2005092310A2 Chemically stable compositions of 4-hydroxy tamoxifen
10/06/2005WO2005092309A1 Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
10/06/2005WO2005092300A1 Method of making silicone pressure sensitive adhesives for delivering hydrophilic drugs using a silicone polyether
10/06/2005WO2005092288A1 Carbohydrate-derivatized liposomes for targeting cellular carbohydrate recognition domains of ctl/ctld lectins, and intracellular delivery of therapeutically active compounds
10/06/2005WO2005092097A1 Compositions and methods for targeting metastatic tumors using multivalent ligand-linked carbohydrate polymers
10/06/2005WO2005091753A2 Flexible vaccine assembly and vaccine delivery platform
10/06/2005WO2005077090A3 Improved methods of producing antibody conjugates
10/06/2005WO2005074897A3 Formulation auxiliary agents (aminopropanoic acid derivative) in cosmetic or dermatological preparations
10/06/2005WO2005059129A3 Adapter for coupling a substance which is to be coupled to a cell surface
10/06/2005WO2005056636A3 Method of preparing maleimide functionalized polymers
10/06/2005WO2005054297A3 Cellulose interpolymers and method of oxidation
10/06/2005WO2005039499A3 Rapidly disintegrating film
10/06/2005WO2005034907A8 Skin care topical ointment
10/06/2005WO2005025518A3 Inhibition of inward sodium currents in cancer
10/06/2005WO2005007077A3 Antimicrobial silver ion complex resinates
10/06/2005WO2005000884A8 Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
10/06/2005WO2004091527B1 Delivery systems of homogeneous thermoreversible low viscosity polymannan gum films
10/06/2005US20050222434 Acid-sensitive compounds, their preparation and uses
10/06/2005US20050222387 Smac-peptides as therapeutics against cancer and autoimmune diseases
10/06/2005US20050222265 Ophthalmic solution
10/06/2005US20050222260 (2S)-2-amino-a-{[2-(ethanimidoylamino) ethyl]thio}butanoic acid, a nitric oxide synthase inhibitor, in stabilized pharmaceutical dosage forms
10/06/2005US20050222214 Administering conjugate having a polyethylene glycol (PEG) moiety covalently bound to the serine residue of antide for therapy of hormonal dependent cancer, endometriosis, uterine fibroids, uterine myoma, and leutinizing hormone (LH) surge in woman undergoing in vitro fertilization
10/06/2005US20050222191 Solution formulations of sirolimus and its analogs for CAD treatment
10/06/2005US20050222182 Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives
10/06/2005US20050222116 Porphyrin oxygen infusion preparation for increasing oxygen concentration in tumor tissue
10/06/2005US20050222086 Inclusion complex of (a) alprazolam in ring-closed form and (b) a water soluble 2-hydroxypropyl-beta-cyclodextrin, adapted for transmucosal delivery; used for treatment of Generalised Anxiety Disorder and panic disorders
10/06/2005US20050222085 Quaternised ammonium cyclodextrin compounds
10/06/2005US20050222064 Polycationic compositions for cellular delivery of polynucleotides
10/06/2005US20050222046 Pharmaceutical preparations of glutathione and methods of administration thereof
10/06/2005US20050222024 Stabilized albumin preparations
10/06/2005US20050222008 Conjugate for treating prokaryotic infections
10/06/2005US20050222001 Stable foamed compositions
10/06/2005US20050221435 Biological material for preparing pharmaceutical compositions intended for treating mammals
10/06/2005US20050221431 Conjugate having a polypeptide targeting moiety including a sequence of human vascular endothelial growth factor, human annexin V, fragment of anthrax lethal factor, or single chain vascular endothelial growth factor covalently bonded via a disulfide bone to a binding moiety such as an adapter protein
10/06/2005US20050221344 Interferon-Like molecules and uses thereof
10/06/2005US20050221284 Heteropolymer complexes and methods for their use
10/06/2005US20050221072 Medical device applications of nanostructured surfaces
10/06/2005US20050220965 For low fat spreads; fractionation, interesterification of blends of stearic acid and palmitic acid
10/06/2005US20050220884 Free-flowing, powdery composition containing alpha-liponic acid (derivates)
10/06/2005US20050220883 Microparticles with adsorbed polypeptide-containing molecules
10/06/2005US20050220881 Pharmaceutical composition
10/06/2005US20050220869 Particulate compositions
10/06/2005US20050220862 Compositions with reduced hepatotoxicity
10/06/2005US20050220861 Colonic release compostion
10/06/2005US20050220859 Methods for treating illnesses of the tracheo-bronchial tract, especially chronic obstructive pulmonary disease (COPD)
10/06/2005US20050220858 Codelivery to a cell of nucleic acid and assistor protein (antigen) where the nucleic acid encodes an antigenic protein or which shares an epitope(s) with the assistor protein; the nucleic acid is entrapped in liposome intravesicular space; assistor protein is on the liposome surface; synergistic
10/06/2005US20050220857 Physiologically compatible, phospholipid-containing, stable and hard matrix
10/06/2005US20050220855 Matrix for administering ergoline compounds such as lisuride; restless leg syndrome; circadian rhythm disorders; Parkinson's disease
10/06/2005US20050220854 Apparatus and method for transdermal delivery of influenza vaccine
10/06/2005US20050220852 Adhesive patch containing tulobuterol
10/06/2005US20050220851 Matrix type patch containing bronchodilators
10/06/2005US20050220850 Topical anhydrous and ethanol-free ascomycin compositions
10/06/2005US20050220831 Poloxamer emulsion preparations
10/06/2005US20050220824 compacted powder slug encapsulated with a film; Tablets; tamper evident capsules
10/06/2005US20050220823 Ophthalmic composition comprising ascomycin
10/06/2005US20050220819 Novel binding epitopes for helicobacter pylori and use thereof
10/06/2005US20050220807 Methods of delivery of exogenous proteins to the cytosol and uses thereof
10/06/2005US20050220806 Method of transporting physiological polymer using protein having rxp repeated sequence
10/06/2005US20050220786 Lyophilised preparation comprising antibodies against the efg receptor
10/06/2005US20050220785 Methods and formulations for reducing circulating antibodies
10/06/2005US20050220780 Pharmaceutical composition having thrombolytic anti-inflammatory and cytoprotective properties
10/06/2005US20050220770 Immobilisation and stabilisation of virus
10/06/2005US20050220762 Modified human interferon polypeptides and their uses
10/06/2005US20050220758 Lyophilised preparation comprising immunocytokines
10/06/2005US20050220756 Nitrosation of a organosulfur polymer; coating medical equipment such as tubes, catheters
10/06/2005US20050220755 Topical composition based on ion-exchange resins, in particular for treating erythemas
10/06/2005US20050220754 Vitamin directed targeting therapy
10/06/2005US20050220752 removing potassium from the gastrointestinal tract with a potassium-binding polymer; an alpha-fluoroacrylic acid polymer, or a difluoromaleic acid polymer crosslinked with vinylsulfonic acid, acrylic acid, vinyl phosphonate, vinyl-1,1-bisphosphonate, vinyl sulfonate, vinyl-1,2-disulfonate, itaconic aci
10/06/2005US20050220717 Steroid solution aerosol products with enhanced chemical stability
10/06/2005US20050220716 Drug delivery assembly
10/06/2005CA2561192A1 Cancerous disease modifying antibodies
10/06/2005CA2560919A1 Uses of anti-ctla-4 antibodies
10/06/2005CA2560905A1 Conjugated psychotropic drugs and uses thereof
10/06/2005CA2560864A1 Cytotoxicity mediation of cells evidencing surface expression of cd63
10/06/2005CA2560862A1 Cytotoxicity mediation of cells evidencing surface expression of mcsp
10/06/2005CA2560859A1 Cytotoxicity mediation of cells evidencing surface expression of cd44
10/06/2005CA2560241A1 Carbohydrate-derivatized liposomes for targeting cellular carbohydrate recognition domains of ctl/ctld lectins, and intracellular delivery of therapeutically active compounds
10/06/2005CA2559029A1 Complex particles and coated complex particles
10/06/2005CA2558884A1 Anhydrous pharmaceutical composition associating a siliconated agent and solubilised active principle
10/06/2005CA2558738A1 Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
10/06/2005CA2558725A1 Conjugates of hydroxyalkyl starch and a protein
10/05/2005EP1582223A1 Vector for gene therapy and method of quantifying target protein in mammal or cultured cells with the administration of the vector for gene theraphy
10/05/2005EP1582222A1 Surface-active agents in powder form for use in tablets and capsules, their process of manufacture and compositions containing them
10/05/2005EP1582221A1 Pharmaceutical oral compositions with a taste masking effect
1 ... 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 ... 1712